Delving into the Latest Updates on Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary) with Synapse

Overview

Basic Info

Drug Type

Growth factors

Synonyms

FGF-2

Target

FGFR1 x FGFR2

Action

stimulants

Mechanism

FGFR1 stimulants(Fibroblast growth factor receptor 1 stimulants), FGFR2 stimulants(Fibroblast growth factor receptor 2 stimulants)

Therapeutic Areas

Otorhinolaryngologic DiseasesOther Diseases

Active Indication

Tympanic Membrane Perforation

Inactive Indication

Furcation DefectsGingival RecessionPeriodontitis

Originator Organization-

Active Organization

NYU Langone Health

Inactive Organization

SVS Institute of Dental Sciences

Massachusetts Eye & Ear Infirmary, Inc.

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is a double blinded, placebo-controlled phase II study evaluating the efficacy of FGF-2 for the treatment of chronic non-healing tympanic membrane perforations (TMP). The documentation of TM closure will be the main efficacy outcome measure. Pretreatment photographs will document the area of the TM perforation and allow measurement of surface areas of the TMP for comparison of pre- and post-treatment. The study will be divided into two phases, the Randomized Treatment phase (part A), and the Unblinded Crossover phase (part B). In part A of the study, subjects will be randomized 1:1 (using simple randomization) to receive FGF-2 or placebo treatment up to 3 treatments. Subjects that fail three study treatments will move on to part B of the study. Subjects who received placebo in part A and failed three placebo treatments will crossover to receive unblinded FGF-2 for up to 3 treatments. Subjects who received FGF-2 in part A and failed three experimental treatments will not have additional FGF-2 treatment, and will move on to study follow up.

Start Date27 May 2022

Sponsor / Collaborator

NYU Langone Health

NCT02307916

/ CompletedPhase 2IIT

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

A Phase II randomized trial will be initiated to evaluate closure of the perforated tympanic membrane as the primary measureable outcome. The goal is to determine the safety and efficacy of Fibroblast Growth Factor-2 (FGF-2) in the closure of chronic tympanic membrane perforations (TMP). If FGF-2 is topically applied for the treatment of chronic TMP in humans, it is hypothesized it will be safe, tolerable and effective for use as treatment for tympanic membrane perforation. A total of 60 subjects will be recruited.

Start Date01 Oct 2016

Sponsor / Collaborator

Massachusetts Eye & Ear Infirmary, Inc.

[+1]

100 Clinical Results associated with Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)

Login to view more data

100 Translational Medicine associated with Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)

Login to view more data

100 Patents (Medical) associated with Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)

Login to view more data

163

Literatures (Medical) associated with Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)

01 Oct 2025·Journal of Dental Sciences

Recombinant human fibroblast growth factor-2 promotes surgical-wound healing in the rat gingiva

Article

Author: Ohgi, Kimiko ; Yamato, Hiroaki ; Maruo, Naoki ; Yoshinaga, Yasunori ; Nakagami, Masanobu ; Tsuchimochi, Nanako ; Sakagami, Ryuji

Background/purpose:

Fibroblast growth factor-2 (FGF-2) has been shown to promote periodontal tissue regeneration in clinical settings. However, reports on the effects of FGF-2 on soft-tissue wound healing after periodontal surgery are scarce. This study aimed to investigate the effects of FGF-2 on gingival wound healing.

Materials and methods:

Seven-week-old male Sprague-Dawley rats were divided into three groups. Each group included 15 rats, with five animals in each experimental period. Five untreated rats were used as the no-treated group. Incisions were made bilaterally in the palatal mucosa from the mesial corner of the maxillary first molar up to the incisor, full-thickness flaps were raised, and sutures were placed. In the control group, no additional treatment was performed, whereas in the FGF-2 and enamel matrix derivative (EMD) groups, FGF-2 and EMD were applied before suturing, respectively. Animals in all groups were euthanized 1, 3, and 7 days, and the maxilla was resected. The re-epithelialization, gingival thickness, inflammation, and angiogenesis were evaluated histopathologically.

Results:

The FGF-2 group showed significantly greater re-epithelialization than the control group on day 1. The FGF-2 group showed significantly greater gingival thickness than the other two groups at all time points. The FGF-2 group showed significantly lesser inflammation than the control group on day 1. The FGF-2 group showed significantly higher angiogenesis than the control group on days 1 and 3.

Conclusion:

FGF-2 promotes re-epithelialization, and increases angiogenesis and gingival thickness. Additionally, FGF-2 reduces the inflammatory response during wound healing.

01 Sep 2024·ARCHIVES OF ORAL BIOLOGY

The role of fibroblast growth factor-2 in modulating the differentiation of periodontal ligament and alveolar bone-derived stem cells

Article

Author: Dal-Fabbro, Renan ; Han, Yuanyuan ; Kaigler, Darnell ; Xu, Jinping ; Bottino, Marco C ; Sexton, Benjamin

OBJECTIVE:

This study examined how range concentrations of Fibroblast Growth Factor-2 (FGF-2) influence the differentiation and activity of human-derived periodontal ligament (hPDLSCs) and alveolar bone-derived stem cells (haBMSCs).

DESIGN:

hPDLSCs and haBMSCs were cultured with varying concentrations of FGF-2 (0, 1, 2.5, 5, 10, 20 ng/mL) and monitored for osteogenic differentiation through alkaline phosphatase (ALP) activity and quantification of gene expression (qRT-PCR) for osteogenesis markers. Additionally, alizarin red staining and a hydroxyproline colorimetric assay evaluated and quantified osteogenic matrix mineralization and collagen deposition. Statistical analyses were performed using one-way ANOVA or two-way ANOVA for multiple comparisons between groups.

RESULTS:

At low FGF-2 concentrations, hPDLSCs differentiated toward an osteogenic lineage, whereas higher concentrations of FGF-2 inhibited osteogenesis and promoted fibroblastic differentiation. The effect of FGF-2 at the lowest concentration tested (1 ng/mL) led to significantly higher ALP activity than osteogenically induced positive controls at early time points and equivalent RUNX2 expression at early and later time points. FGF-2 supplementation of haBMSC cultures was sufficient, at all concentrations, to increase ALP activity at an earlier time point. Mineralization of haBMSC cultures increased significantly within 5-20 ng/mL FGF-2 concentrations under basal growth media conditions (α-minimal essential medium supplemented with 15 % fetal bovine serum and 1 % penicillin/streptomycin).

CONCLUSIONS:

FGF-2 has a dual capacity in promoting osteogenic and fibroblastic differentiation within hPDLSCs contingent upon the dosage and timing of administration, alongside supporting osteogenic differentiation in haBMSCs. These findings underscore the need for precision growth factors dosing when considering the design of biomaterials for periodontal regeneration.

01 Aug 2023·Journal of periodontal research

The role of rhFGF-2 in periodontal defect bone fill: A systematic review of the literature.

Review

Author: Batas, Leonidas ; Fragkioudakis, Ioannis ; Pouliou, Maria-Myrsini ; Doufexi, Aikaterini-Elisavet

BACKGROUND:

Growth factors have been used with success in periodontal regeneration, especially in intrabony defects. Among those, the recombined form of fibroblast growth factor-2 (rhFGF-2) has been also examined.

OBJECTIVE:

To address the outcomes of periodontal regeneration using rhFGF-2 alone or in combination with bone substitutes primarily in terms of Radiographic Bone Fill (RBF%) and secondary Probing Pocket Depth (PPD), and Probing Attachment Levels (PAL).

MATERIAL AND METHODS:

A search in MEDLINE and EMBASE using the Ovid interface was conducted from 2000 up to and including the 12th of November 2022. Starting from the initially identified 1289 articles, 34 studies were selected for further analysis. Following the full-text screening, 7 of the 34 studies met the inclusion criteria and thus were included in the systematic review after assessing their quality according to the Newcastle-Ottawa scale (NOS). Clinical and radiographic results (bone gain, pocket depth, and clinical attachment level) after the application of FGF-2 alone or in combination with different carriers were studied in patients with intrabony defects of at least one wall and pocket depth greater than 4 mm.

RESULTS:

Primary outcomes: RBF% was higher in studies using a combination of rhFGF-2 and bone substitutes (74.6 ± 20.0%) compared to others using the specific growth factor alone or negative controls (22.7 ± 20.7%). In terms of secondary outcomes, the analysis failed to show an additional benefit from the use of the rhFGF-2 alone or in combination with bone substitutes.

CONCLUSION:

rhFGF-2 can improve RBF% in the treatment of periodontal defects, especially when it is used in combination with a bone substitute.

100 Deals associated with Human Fibroblast Growth Factor 2(Massachusetts Eye and Ear Infirmary)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tympanic Membrane Perforation	Phase 2	United States	Massachusetts Eye & Ear Infirmary, Inc.	01 Oct 2016
Furcation Defects	Phase 1	India	SVS Institute of Dental Sciences	01 May 2019
Gingival Recession	Phase 1	India	SVS Institute of Dental Sciences	01 May 2019
Periodontitis	Phase 1	India	SVS Institute of Dental Sciences	01 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02307916 (CTgov)	Phase 2	Tympanic Membrane Perforation	57	FGF-2 (FGF-2)	dqocaslquf = htihniozso obdefoyafr (qluccouitd, wiyeihjdkg - pfivtdbgwc) View more	-	11 Jun 2020
				Placebo (Placebo)	dqocaslquf = hkmveyuxxa obdefoyafr (qluccouitd, wzmsajuytu - nyxznlvhwp) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data